- Exchange: NASDAQ GS
- Sector: Health Care
- Industry: Biotech & Pharma
- Sub-Industry: Biotech
Snapshot for InterMune Inc (ITMN)
| Open: | 9.8400 | Day's Range: | 9.7000 - 9.9200 | Volume: | 542,186 |
|---|---|---|---|---|---|
| Previous Close: | 9.8300 | 52wk Range: | 7.2100 - 12.7700 | 1-Yr Rtn: | -19.39% |
Key Statistics for ITMN
| Current P/E Ratio (ttm) | - |
|---|---|
| Estimated P/E(12/2013) | - |
| Relative P/E vs. SPX | - |
| Earnings Per Share (USD) (ttm) | -3.0500 |
| Est. EPS (USD) (12/2013) | -2.7400 |
| Est. PEG Ratio | - |
| Market Cap (M USD) | 803.95 |
| Shares Outstanding (M) | 81.62 |
| 30 Day Average Volume | 1,108,490 |
| Price/Book (mrq) | 4.8886 |
| Price/Sale (ttm) | 21.2929 |
| Dividend Indicated Gross Yield | -% |
| Cash Dividend | - |
| Last Dividend | |
| 5 Year Dividend Growth | - |
| Next Earnings Announcement | 07/23/2013 |
mrq = Most Recent Quarter; ttm = Trailing Twelve Months
Income Statement for ITMN
Company Profile & Key Executives for ITMN
InterMune, Inc. is a biotechnology company. The Company's focus is on the research, development and commercialization of therapies in pulmonology and fibrotic diseases. InterMune's research programs are focused on the discovery of targeted, small-molecule therapeutics and biomarkers to treat and monitor pulmonary and fibrotic diseases.
| Daniel G Welch "Dan"Chairman/President/CEO | John HodgmanExec VP:Finance & Admin/CFO |
| Giacomo Di NepiExec VP/Mng Dir:Europe | Jonathan A LeffExec VP:Research & Development |
Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.
Sponsored Financial Commentaries
Advertisement
Top Forex Trading Resources
-
ITMN News
-
Industry News
Advertisement
Advertisement
Sponsored Links
Advertisements
Rate this Page